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ABSTRACT
Objective Cognitive–behavioural therapy (CBT) has 
been shown to be effective in the management of 
chronic widespread pain (CWP); we now test whether it 
can prevent onset among adults at high risk.
Methods A population- based randomised controlled 
prevention trial, with recruitment through UK general 
practices. A mailed screening questionnaire identified 
adults at high risk of CWP. Participants received either 
usual care (UC) or a short course of telephone CBT 
(tCBT). The primary outcome was CWP onset at 12 
months assessed by mailed questionnaire. There were 
seven secondary outcomes including quality of life 
(EuroQol Questionnaire- five dimensions- five levels/EQ- 
5D- 5L) used as part of a health economic assessment.
Results 996 participants were randomised and included 
in the intention- to- treat analysis of which 825 provided 
primary outcome data. The median age of participants 
was 59 years; 59% were women. At 12 months there 
was no difference in the onset of CWP (tCBT: 18.0% vs 
UC: 17.5%; OR 1.05; 95% CI 0.75 to 1.48). Participants 
who received tCBT were more likely to report better 
quality of life (EQ- 5D- 5L utility score mean difference 
0.024 (95% CI 0.009 to 0.040)); and had 0.023 (95% 
CI 0.007 to 0.039) more quality- adjusted life- years at 
an additional cost of £42.30 (95% CI −£451.19 to 
£597.90), yielding an incremental cost- effectiveness ratio 
of £1828. Most secondary outcomes showed significant 
benefit for the intervention.
Conclusions A short course of tCBT did not prevent 
onset of CWP in adults at high risk, but improved quality 
of life and was cost- effective. A low- cost, short- duration 
intervention benefits persons at risk of CWP.
Trial registration number  ClinicalTrials. gov Registry 
(NCT02668003).
INTRODUCTION
Chronic widespread pain (CWP) is common, with 
an estimated population prevalence of 10.6% (95% 
CI 8.6% to 12.9%)1 and is the key feature of fibro-
myalgia which is the second most common reason 
(after osteoarthritis) for referral to a rheumatolo-
gist.2 CWP and fibromyalgia result in a substantial 
impact on health- related quality of life3 even in 
comparison with other musculoskeletal disorders.4
The road to diagnosis is often tortuous and can 
take many years. Using general practitioner records 
in the UK, Hughes et al5 noted that people diagnosed 
with fibromyalgia had higher rates of primary care 
visits (average 25 visits/year), prescriptions (11/
year) and testing from at least 10 years prior to 
diagnosis, in comparison with matched persons 
without such a diagnosis (12 visits/year and 4.5 
prescriptions/year). Current European guidelines 
emphasise the primary role of non- pharmacological 
therapies for fibromyalgia.6 Evidence in relation to 
musculoskeletal pain generally, is that the longer 
the duration of symptoms the less likely they are 
to improve, including with specific interventions.7
A Versus Arthritis ‘Research roadmap for pain’ 
produced by scientists, clinicians and patients iden-
tified preventing future musculoskeletal pain as 
one of four main priorities.8 Further recognising its 
importance, the International Association for the 
Study of Pain nominated 2020 as ‘The Global Year 
for the Prevention of Pain’. Despite this, we are not 
aware of any large- scale trials which have tested 
approaches to the future prevention of pain.
We have previously shown, in a randomised 
controlled trial, short- term and long- term effective-
ness of a course of cognitive–behavioural therapy 
delivered by telephone (tCBT) for CWP, compared 
Key messages
What is already known about this subject?
 ► Cognitive–behavioural therapy (CBT) has 
demonstrated long- term effectiveness in 
managing chronic widespread pain (CWP), the 
characteristic symptom of fibromyalgia.
 ► It improves patient global assessment of change 
and quality of life.
What does this study add?
 ► A short course of telephone CBT in persons 
evaluated at high risk of developing CWP 
does not change onset of CWP but does result 
in a wide range of health benefits including 
improved quality of life.
How might this impact on clinical practice or 
future developments?
 ► CBT derives benefit for a wider group of 
people with pain than previously established 
and in relation to this wider group is highly 
cost- effective.
 on F
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with usual care (UC).9 10 These results are consistent with a meta- 
analysis of 29 trials involving 2509 participants and comparing 
CBT (across all modes of delivery) with control interventions 
for the management of fibromyalgia, which found high- quality 
evidence for improving pain and reducing disability, negative 
mood and fatigue.11
We have developed, validated and refined a statistical model 
which identifies people at high risk for the future development 
of CWP.12 13 On the basis of reporting somatic symptoms, sleep 
problems and aspects of illness behaviour, those classified as 
‘high risk’ have around one in four chance of reporting CWP 
1 year later. Therefore, building on the evidence for the use of 
tCBT in the management of CWP and the ability to identify 
those with risk factors for its development, we undertook a trial 




We conducted a randomised controlled parallel prevention trial, 
recruiting through a population- based sampling frame, in three 
health boards within the UK (National Health Service (NHS) 
Grampian, NHS Greater Glasgow and Clyde, and NHS High-
land), the protocol for which has been previously published.14 
Recruitment was through 16 general practices.
Participants
A short screening questionnaire, to determine eligibility for the 
trial, was mailed to persons aged 25 years and over registered 
at participating general practices in the study area. Respon-
dents eligible for the trial were those assessed as at high risk 
of developing CWP, namely that they reported pain which did 
not satisfy the definition of CWP used in the 1990 American 
College of Rheumatology criteria for fibromyalgia (namely axial 
and contralateral body pain present for at least 3 months), and 
hereafter referred to as ‘ACR criteria’,15 and satisfied at least 
two of the following: (a) a score >4 on the Illness Behaviour 
Subscale of the Illness Attitudes Scale,16 (b) a score >2 on the 
Somatic Symptom Scale score (but excluding items on pain),17 
(c) a score >4 on the Sleep Problem Scale.18 In order to ensure 
that in the event of the trial showing benefit there was a relevant 
clinical population to which the intervention could be applied, 
we added to the risk models we had developed the requirement 
that persons had consulted to primary care within the previous 
6 months or reported consulting a doctor frequently. Respon-
dents were not eligible to take part if they had a medical condi-
tion which would make the proposed intervention unsuitable 
(eg, lacked cognitive ability).
Randomisation
Potentially eligible participants were contacted by post with 
information about the study, and subsequently by a study 
researcher by telephone to confirm their willingness to take part 
and provide informed consent. Participants were allocated into 
groups using a computer randomisation program (1:1 allocation 
ratio), stratified in blocks by two factors (a) the number of non- 
pain ‘high- risk’ factors they reported (two or three) since this is 
related to the risk of CWP onset, and (b) the general practice at 
which they were registered.
Procedures
The tCBT intervention consisted of an initial assessment 
(45–60 min), six weekly sessions (each 30–45 min) over 6 weeks, 
and then booster sessions at 3 and 6 months. The intervention 
was delivered by therapists trained for the study and accredited 
by the British Association for Behaviour and Cognitive Psycho-
therapies. Participants were supported by a self- management 
manual. The therapist conducted an assessment for problem 
identification, and they developed with each participant a shared 
formulation of the current health problem. The sessions involved 
education about musculoskeletal pain, somatic symptoms and 
specific techniques such as pacing of activity, behavioural acti-
vation, diary keeping, identifying and challenging negative and 
unhelpful thinking patterns, and the development of a longer 
term management plan. Participants would record in the manuals 
agreed goals for the therapist and patient to work towards, and 
some activities to complete between sessions. Therapists deliv-
ering the intervention received a 2- day training programme 
conducted by the investigators. Therapists were supervised every 
2 weeks (by investigators KL and PK) throughout the delivery 
of the intervention. The number of telephone consultations 
conducted was recorded, although the therapist and participant 
could jointly agree that no further sessions were required before 
all planned sessions had been completed.
The group allocated to UC received no additional interven-
tion, reflecting the fact there is no specific intervention provided 
to patients currently for the prevention of CWP. There was no 
restriction on what this care could involve.
Follow- up questionnaires were mailed to participants at 3, 12 
and 24 months after the treatment start date (for participants in 
the active treatment group) or dummy treatment start date (for 
those in UC). The dummy treatment start date for a participant 
randomised to UC was determined by the treatment start date of 
the last participant to be randomised to receive active treatment. 
At 3 and 12 months, participants who did not return their ques-
tionnaire were telephoned to ask them to complete and return 
it, while at 24 months the follow- up call also offered the option 
of completing a shortened version by telephone.
Outcomes
The principal outcome time was at 12- month follow- up and 
the primary outcome was ACR criteria for CWP. Secondary 
outcomes were: Global Impression of Change, Illness Behaviour 
Subscale of the Illness Attitudes Scale,16 the Somatic Symptom 
Scale (excluding items on pain),17 the Sleep Problem Scale,18 the 
presence of pain over the past month, Widespread Pain Index 
(WPI) and Symptom Severity Scale (SSS) of the 2010 (revised) 
criteria for fibromyalgia,19 psychological distress measured using 
the General Health Questionnaire (GHQ),20 Chalder Fatigue 
Scale,21 quality of life (EuroQol Questionnaire- five dimensions- 
five levels/EQ- 5D- 5L)22 and capability (ICEpop CAPability 
measure for Adults/ICECAP- A).23 Further details of secondary 
outcome (including coding) are given in the online supplemental 
file.
Statistical analysis
All analyses were undertaken using Stata V.15. The a priori 
target sample size was 946 participants, which would provide 
90% power to detect a group difference of 9% (21% vs 12%) in 
the percentage of participants with CWP at 12- month follow- up, 
assuming a 5% significance level and an 80% response rate.
Where there were missing data within a scale score, we 
followed standard procedures (where available) as to if and how 
the missing values could be imputed. The analysis of the primary 
outcome used a binary logistic regression model with results 
expressed as an OR with 95% CI. Secondary outcomes were 
 on F
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analysed using linear, binary logistic, ordinal logistic or Poisson 
regression models for continuous, binary, ordinal and count 
variables, respectively. Model results were reported using mean 
differences, ORs or incidence rate ratios (IRRs) as appropriate. 
Except for EQ- 5D- 5L, mean differences less than 0 and ORs/IRRs 
less than 1 favour the treatment group. All models were adjusted 
(adj) for the number of non- pain risk factors on screening (two 
or three), age (years), gender, general practice (random effect) 
and baseline score of the outcome measure (where applicable). 
The primary analysis was by intention to treat—that is, partic-
ipants were analysed according to randomised group regard-
less of the number of sessions received. Separate analyses were 
performed for each time point (3, 12 and 24 months). For the 
primary outcome, a p value less than 0.05 was regarded as statis-
tically significant; for secondary outcomes p<0.01 was used. 
Additional sensitivity analyses were conducted for the primary 
outcome only and are detailed in the online supplemental file.
Health economic analysis
Health service resource used over 24 months was assessed using 
responses from self- reported questionnaires. Participants were 
asked to recall their usage for the previous 4- week period at 
each follow- up. Resource use was then valued using published 
UK sources—NHS Reference Cost and the Personal and Social 
Service Research Unit for NHS primary and secondary care, and 
published literature for care obtained from private providers.24 
The unit costs used for the valuation of health service resource 
use are reported in online supplemental table S1. The interven-
tion cost was based on the actual number and duration of tele-
phone calls per participant (‘direct time’), plus time spent on 
training and supervision. An allowance for indirect time spent 
was also included and this was based on an assumed ratio of 1:1 
between time spent on participant contact and other activities 
conducted by therapists. Training costs were estimated using the 
time spent in training by trainers and trainees (tCBT therapists). 
A fortnightly supervision cost was estimated by assuming 30 
sessions per therapist (30 min per session) were provided. Costs 
were expressed in 2017/2018 prices. Health utility scores were 
assigned based on responses to the EQ- 5D- 5L at each follow- up, 
and these were converted using the ‘crosswalk’ procedure to 
EQ- 5D- 3L.25 There is currently no consensus on the preferred 
EQ- 5D- 5L tariff for use in economic evaluation, although the 
National Institute for Health and Care Excellence (NICE) recom-
mends the use of the ‘crosswalk’ procedure (a validated mapping 
function) to derive health utility scores for the EQ- 5D- 5L from 
the EQ- 5D- 3L tariff (https://www. nice. org. uk/ about/ what- we- 
do/ our- programmes/ nice- guidance/ technology- appraisal- guid-
ance/ eq- 5d- 5l accessed 20 November 2020). These utility scores 
were used to estimate quality- adjusted life- years (QALYs) over 
the 24 months using the area under the curve method.26 Costs 
and QALYs incurred beyond 12 months were discounted at the 
rate of 3.5% per annum.
The within- trial economic analysis was conducted over 
24 months from a UK NHS cost perspective. To estimate the 
differences in mean costs and QALYs between groups, gener-
alised linear models with adjustment for minimisation factors, 
baseline cost and baseline utility score were performed. A γ 
family with log- link function and a Poisson family with power 
0.5 link function were specified for the cost and QALY data, 
respectively. Missing data were addressed using multiple impu-
tation by chained equations (MICE). Variance surrounding the 
incremental costs and QALYs was characterised using non- 
bootstrapping (500 iterations), with MICE (m=5) nested within 
the bootstrap loops.27 Cost- effectiveness acceptability curves 
were constructed, using 500 replications of each incremental 
cost- effectiveness ratio (ICER) and the net monetary benefit 
framework, to determine the probability of the alternative inter-
ventions being considered cost- effective at different willing-
ness to pay per QALY (£20 000–£30 000 per QALY used are 
commonly applied ceiling ratios in the UK). Several sensitivity 
analyses were performed to explore the impact on the results of 
uncertainty in estimates made—(1) using complete cases of costs 
and QALYs, (2) including private care costs, (3) using alternative 
tCBT costing methodology (actual trial expenses incurred by 
therapists and the cost of a complete tCBT course) and (4) using 
ICECAP tariff as the measure of effectiveness.
The trial was evaluated by the Trial Steering Committee as not 
requiring a Data Monitoring Committee.
RESULTS
Of 61 257 screening questionnaires sent between 4 April 2016 
and 4 November 2016 to patients registered at 16 general prac-
tices, 18 035 completed questionnaires were returned. From 
those returning a completed questionnaire, 2406 were identi-
fied as potentially eligible and sent invitations to take part in the 
trial. A total of 1002 participants were recruited to the trial and 
randomised, 501 to tCBT and 501 to UC, between May 2016 
and March 2017. Six participants were subsequently determined 
to be ineligible for the trial and were excluded from analyses (see 
Trial profile: figure 1) leaving a final study size of 500 and 496 in 
the tCBT and UC arms, respectively. At the 3- month, 12- month 
Figure 1 Trial profile. tCBT, telephone- delivered cognitive–behavioural 
therapy.
 on F









is: first published as 10.1136/annrheum





4 Macfarlane GJ, et al. Ann Rheum Dis 2021;0:1–9. doi:10.1136/annrheumdis-2020-219091
Pain
and 24- month follow- up, there were 823, 825 and 853 respon-
dents who provided primary outcome data, respectively. Most 
participants (51%) came from the lowest two quintiles of depri-
vation, while 18% came from the two most deprived quintiles.
Participants at the time of recruitment had a median age of 59 
years (IQR 48–69), 59% were women, and 52% were working 
full- time or part- time (table 1). The median EQ- 5D utility score 
was 0.74 (IQR 0.65–0.80). The vast majority satisfied only two 
of the non- pain criteria for eligibility, nearly always on the basis 
of a high score on the illness behaviour subscale of the Illness 
Attitudes Scale and having sleep problems. Only 6% of the study 
sample satisfied the somatic symptoms criterion. The tCBT and 
UC groups were well matched in terms of the measured health- 
related factors.
Results for all outcome measures at the primary time point 
(12 months) are shown in table 2. The corresponding results 
at 3 and 24 months are shown in online supplemental tables 
S2–S3. Table 3 provides a summary of all primary and secondary 
outcomes at all time points and shows adjusted and unadjusted 
effect sizes.
Primary outcome
At the 12- month time point similar percentages in the tCBT and 
UC groups reported having CWP (tCBT: 69/384 (18.0%), UC: 




tCBT (n=500) Usual care (n=496)
Median (IQR) Median (IQR)
Age (years) 58.8 (47.7–68.7) 59.5 (47.9–68.9)
  N (%) N (%)
Gender
  Male 209 (41.8) 204 (41.0)
  Female 291 (58.2) 292 (58.9)
Employment status
  Working (full or part- time) 277 (55.4) 244 (49.2)
  Unable to work because 
of health
18 (3.6) 30 (6.0)
  Retired 168 (33.6) 177 (35.7)
  Other 37 (7.4) 45 (9.1)
CWP risk profile:
Illness behaviour score >4
  No 1 (0.2) 2 (0.5)
  Yes 498 (99.6) 494 (99.5)
  Not known* 1 (0.2) 0 (0.0)
Somatic Symptom Scale score >2
  No 472 (94.4) 462 (93.1)
  Yes 28 (5.6) 34 (6.9)
Sleep problems score >4
  No 1 (0.2) 2 (0.4)
  Yes 499 (99.8) 493 (99.4)
  Not known* 0 (0.0) 1 (0.2)
CWP risk profile factors present (N)
  2 474 (94.8) 466 (94.0)
  3 26 (5.2) 30 (6.0)
  Median (IQR) (n)† Median (IQR) (n)
Psychological distress (GHQ) 1 (0–4) (499) 1 (0–4) (494)
Quality of Life (EQ- 5D- 5L 
utility score)
0.74 (0.65–0.80) (499) 0.74 (0.64–0.80) (496)
ICECAP- A 0.91 (0.81–0.95) (495) 0.90 (0.79–0.95) (491)
Fibromyalgia research criteria
  WPI 3 (1–4) (499) 2 (1–4) (492)
  SSS 4 (3–6) (497) 4 (3–5) (494)
*Where individuals completed half or fewer items, the score was classified as 
not known, but individuals could still be eligible for recruitment based on their 
responses to other items answered.
†The number of persons for whom a scale score could be calculated.
EQ- 5D- 5L, EuroQol Questionnaire- five dimensions- five levels; GHQ, General Health 
Questionnaire; ICECAP- A, ICEpop CAPability measure for Adults; ITT, intention to 
treat; SSS, Symptom Severity Scale; tCBT, telephone- delivered cognitive–behavioural 
therapy; WPI, Widespread Pain Index.




tCBT (n=500) Usual care (n=496)
Primary outcome N (%) N (%)
Chronic widespread pain
  No 315 (82.0) 364 (82.5)
  Yes 69 (18.0) 77 (17.5)
Secondary outcome
Global impression of change
  Very much better 24 (6.5) 15 (3.5)
  Much better 88 (23.7) 59 (13.8)
  A little better 90 (24.3) 84 (19.6)
  No change 83 (22.4) 126 (29.4)
  A little worse 65 (17.5) 119 (27.7)
  Much worse 18 (4.9) 23 (5.4)
  Very much worse 3 (0.8) 3 (0.7)
Pain reported
  No 79 (20.6) 68 (15.4)
  Yes 305 (79.4) 373 (84.6)
CWP risk profile
Somatic symptoms score
  0 210 (56.5) 228 (52.8)
  1 103 (27.7) 123 (28.5)
  2–5 59 (15.9) 81 (18.8)
Illness behaviour score, mean 
(SD) (n)*
8.21 (4.04) (371) 8.96 (4.19) (431)
Sleep problems score, mean 
(SD) (n)
8.20 (4.89) (373) 9.20 (5.16) (432)
Psychological distress (GHQ score)
  0 201 (54.5) 202 (46.8)
  1 59 (16.0) 54 (12.5)
  2–5 68 (18.4) 113 (26.2)
  6–12 41 (11.1) 63 (14.6)
  Mean (SD) (n) Mean (SD) (n)
Chalder Fatigue Score 12.6 (4.5) (370) 13.6 (4.4) (433)
  Median (IQR) (n) Median (IQR) (n)
Quality of Life (EQ- 5D utility 
score)
0.74 (0.66–0.84) (371) 0.74 (0.65–0.82) 
(435)
ICECAP- A 0.91 (0.82–0.97) (368) 0.89 (0.78–0.95) 
(429)
Fibromyalgia research criteria
  WPI 2 (1–4) (366) 2 (1–4) (427)
  SSS 3 (2–5) (369) 4 (2–5) (431)
*The number of persons for whom a scale score could be calculated.
EQ- 5D, EuroQol Questionnaire- five dimensions; GHQ, General Health Questionnaire; 
ICECAP- A, ICEpop CAPability measure for Adults; SSS, Symptom Severity Scale; tCBT, 
telephone- delivered cognitive–behavioural therapy; WPI, Widespread Pain Index.
 on F









is: first published as 10.1136/annrheum





5Macfarlane GJ, et al. Ann Rheum Dis 2021;0:1–9. doi:10.1136/annrheumdis-2020-219091
Pain
77/441 (17.5%); adj OR 1.05; 95% CI: 0.75 to 1.48; difference 
in percentages: adj 0.73, 95% CI: −4.15 to 5.61) (tables 2 and 3)). 
Very similar results were obtained at 3 months (17.9% vs 16.9%; 
adj OR: 1.08; 95% CI: 0.74 to 1.58) and 24 months (19.6% vs 
22.3%; adj OR: 0.85; 95% CI: 0.68 to 1.07) (online supple-
mental tables S2–S3, table 3). There was no difference in the 
interpretation when examining unadjusted results, per protocol 
results or the analyses using multiple imputation (table 3). The 
generalised estimating equations model, incorporating data from 
all three time points, also showed no evidence of a difference 
(adj OR: 1.00; 95% CI: 0.96 to 1.04; p=0.91).
Secondary outcomes
At 12 months, those randomised to tCBT were more likely to 
perceive their health to be improved (adj OR (ordinal logistic 
regression/OLR): 0.51, 95% CI: 0.39 to 0.67) and to report better 
quality of life (EQ- 5D- 5L utility scores) (adj mean difference 






Adjusted† effect size 
(95% CI) P value
Unadjusted effect size 
(95% CI) P value
Primary outcome   
CWP
CWP (per protocol)
CWP (with multiple imputation)
3 Logistic regression (OR) 1.08 (0.74 to 1.58) 0.691 1.07 (0.75 to 1.53) 0.716
1.15 (0.75 to 1.75) 0.519 1.18 (0.77 to 1.66) 0.522
1.06 (0.74 to 1.54) 0.749 1.05 (0.72 to 1.53) 0.816
CWP‡
CWP (per protocol)
CWP (with multiple imputation)
12 1.05 (0.75 to 1.48) 0.771 1.04 (0.72 to 1.48) 0.849
1.11 (0.81 to 1.50) 0.519 1.09 (0.74 to 1.60) 0.673
1.04 (0.75 to 1.45) 0.982 1.03 (0.74 to 1.42) 0.964
CWP
CWP (per protocol)
CWP (with multiple imputation)
24 0.85 (0.68 to 1.07) 0.163 0.84 (0.61 to 1.18) 0.317
0.85 (0.64 to 1.12) 0.241 0.84 (0.58 to 1.20) 0.330
0.85 (0.66 to 1.09) 0.220 0.84 (0.65 to 1.09) 0.196
CWP 3, 12, 24 GEE (OR) 1.00 (0.96 to 1.04) 0.923 1.00 (0.96 to 1.04) 0.835
Secondary outcomes
Global impression of change§ 3 Ordinal logistic 
regression (OR)
0.42 (0.32 to 0.55) <0.001 0.43 (0.34 to 0.56) <0.001
12 0.51 (0.39 to 0.67) <0.001 0.53 (0.41 to 0.68) <0.001
24 0.55 (0.43 to 0.70) <0.001 0.58 (0.45 to 0.73) <0.001
  CWP risk profile Somatic symptoms score 3 Ordinal logistic 
regression (OR)
0.79 (0.60 to 1.03) 0.084 0.83 (0.64 to 1.08) 0.173
12 0.86 (0.71 to 1.04) 0.112 0.85 (0.65 to 1.11) 0.237
24 0.81 (0.59 to 1.12) 0.206 0.90 (0.67 to 1.21) 0.498
Illness behaviour score 3 Linear regression (mean 
difference)
−0.17 (−0.58 to 0.24) 0.385 −0.25 (−0.79 to 0.29) 0.360
12 −0.81 (−1.54 to −0.09) 0.030 −0.74 (−1.32 to −0.17) 0.011
24 −1.25 (−2.15 to −0.35) 0.010 −1.20 (−1.83 to −0.58) <0.001
Sleep problems score 3 Linear regression (mean 
difference)
−0.62 (−1.26 to 0.02) 0.057 −0.62 (−1.31 to 0.08) 0.081
12 −0.95 (−1.48 to −0.42) 0.002 −1.00 (−1.70 to −0.30) 0.005
24 −0.51 (−1.25 to 0.23) 0.161 −0.52 (−1.39 to 0.16) 0.117
Psychological distress (GHQ) 3 Ordinal logistic 
regression (OR)
0.55 (0.43 to 0.69) <0.001 0.58 (0.45 to 0.76) <0.001
12 0.65 (0.50 to 0.86) 0.002 0.70 (0.54 to 0.90) 0.007
24 0.76 (0.60 to 0.96) 0.024 0.74 (0.56 to 0.98) 0.037
Chalder Fatigue Score 3 Linear regression (mean 
difference)
−1.36 (−2.10 to −0.64) 0.001 −1.40 (−1.97 to −0.82) <0.001
12 −1.02 (−1.63 to −0.42) 0.003 −1.03 (−1.64 to −0.42) 0.001
24 −0.93 (−1.62 to −0.23) 0.012 −0.93 (−1.58 to −0.27) 0.006
Quality of Life (EQ- 5D- 5L utility score) 3 Linear regression (mean 
difference)
0.009 (−0.009 to 0.028) 0.304 0.021 (−0.004 to 0.046) 0.101
12 0.024 (0.009 to 0.040) 0.004 0.037 (0.010 to 0.064) 0.007
24 0.030 (0.009 to 0.050) 0.008 0.040 (0.011 to 0.069) 0.007
ICECAP- A tariff 3 Ordinal logistic 
regression (OR)
1.14 (0.89 to 1.48) 0.304 1.17 (0.86 to 1.59) 0.323
12 1.39 (0.94 to 2.04) 0.096 1.39 (1.01 to 1.91) 0.042
24 0.88 (0.67 to 1.15) 0.338 0.99 (0.70 to 1.41) 0.966
  Fibromyalgia criteria Widespread Pain Index 3 Poisson regression (IRR) 0.98 (0.90 to 1.07) 0.698 1.01 (0.93 to 1.10) 0.771
12 0.88 (0.80 to 0.98) 0.018 0.92 (0.84 to 0.99) 0.036
24 0.88 (0.78 to 0.98) 0.022 0.92 (0.84 to 1.00) 0.058
Symptom Severity Scale 3 Linear regression (mean 
difference)
−0.28 (−0.52 to −0.04) 0.026 −0.25 (−0.57 to 0.65) 0.118
12 −0.52 (−0.75 to −0.28) <0.001 −0.59 (−0.91 to −0.27) <0.001
24 −0.29 (−0.55 to −0.02) 0.040 −0.28 (−0.61 to 0.05) 0.100
*Analyses shaded in grey favour tCBT over usual care at prespecified significance level for secondary outcomes (p<0.01). Except for EQ- 5D- 5L, mean differences less than 0 and ORs less than 1 
favour the treatment group.
†Adjusted analyses control for the number of risk factors (two or three), age, gender, baseline score (if applicable) and centre (random effect). Analyses are intention to treat unless otherwise 
stated.
‡Primary outcome.
§OR of 1 point increase in global impression of change score (worsening of health).
CWP, chronic widespread pain; EQ5D- 5D- 5L, EuroQol Questionnaire- five dimensions- five levels; GEE, generalised estimating equations; GHQ, General Health Questionnaire; ICECAP- A, ICEpop 
CAPability measure for Adults; IRR, incidence rate ratio; ;tCBT, telephone- delivered cognitive–behavioural therapy.
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(diff): 0.024, 95% CI: 0.009 to 0.040) (tables 2 and 3). While 
those who received tCBT had lower illness behaviour (adj mean 
diff: −0.81; 95% CI: −1.54 to −0.09) and sleep problem scores 
(adj mean diff: −0.95; 95% CI: −1.48 to −0.42), but there 
was no significant difference in relation to somatic symptoms 
(adj OR: 0.86; 95% CI: 0.71 to 1.04). Participants randomised 
to tCBT had improved distress (GHQ scores) (adj OR: 0.65, 
95% CI: 0.50 to 0.86) and lower levels of fatigue (Chalder Scale 
scores) (adj mean diff: −1.02, 95% CI: −1.63 to −0.42). There 
was no evidence of a difference for ICECAP- A tariffs (adj OR 
(OLR): 1.39, 95% CI: 0.94 to 2.04; p=0.10). In relation to the 
components of criteria for fibromyalgia, they had lower scores 
on the WPI (adj IRR: 0.88; 95% CI: 0.80 to 0.98) and SSS (adj 
mean diff: −0.52, 95% CI: −0.75 to −0.28). Of these receiving 
tCBT, 3.8% met fibromyalgia research criteria at follow- up (in 
comparison to 6.0% among those receiving UC).
Outcomes across time points
Sensitivity analyses, unadjusted results and findings at 3- month 
and 24- month time points generally yielded similar observations 
as those for 12 months (table 3, online supplemental tables S1–
S2). There was consistently no effect on the primary outcome. 
The strongest and most consistent effects were on patient global 
assessment of change—which showed large and consistent 
effects across all time points. There were also clear effects of the 
intervention (in comparison with UC) across all time points with 
respect to improvement in levels of fatigue and psychological 
distress. Quality of life was better in the intervention group from 
12 months onwards. There was only one serious adverse event 
reported, it was in the intervention group but unrelated to the 
intervention.
Health economic analysis
The unadjusted health service resource use and costs per partic-
ipant are summarised in online supplemental table S4. Partici-
pants randomised to tCBT group had an average time of 139 min 
of direct contact with therapists over the 6- month t- CBT 
course, and the average tCBT cost was £270.19 per participant. 
Compared with the UC group, NHS primary and secondary 
care costs were lower among tCBT group, and private care costs 
higher. All cost- effectiveness analyses showed that tCBT was 
associated with an increase in health service costs and an increase 
in QALYs (table 4). The primary analysis generated a mean of 
0.023 (95% CI 0.007 to 0.039) more QALYs per participant at 
an additional cost of £42.30 (95% CI −£451.19 to £597.90), 
yielding an ICER of £1828. Based on the results of the non- 
parametric bootstrap, tCBT was found to have a 91.6% chance 
of being the preferred strategy at a ceiling ratio of £20 000 per 
QALY gained (figure 2). Sensitivity analyses showed that this 
finding was robust to changes in study perspective, inclusion 
of complete cases only and different assumptions relating to 
delivery of the intervention in terms of tCBT staff time (online 
supplemental figure S1 a–d).
DISCUSSION
A short course of tCBT among persons at high risk did not 
change the proportion of people developing CWP (compared 
with UC). Those receiving the active intervention were more 
likely to perceive their health as having improved and report 
better quality of life as well as lower levels of fatigue and psycho-
logical distress. The intervention was highly cost- effective in 
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Undertaking a primary prevention study presents different 
challenges to undertaking a treatment study. Most people eligible 
for the trial probably would not have known what CWP is, nor 
that they were at high risk of its development. Thus, the inter-
vention was described as ‘maintaining musculoskeletal health’ 
and introduced in the context of participants having reported 
pain and other symptoms. Although a set number of sessions for 
the intervention was planned, it was agreed that at any point the 
intervention could be stopped with mutual agreement between 
therapist and participant; with the intervention considered 
completed. Among participants, 329 (66%) were considered to 
be completers that is, had the assessment session and either had 
at least two completed treatment sessions (n=297) or had the 
assessment session and up to one treatment session with mutual 
agreement that the intervention was complete (n=32). Of those 
classed as ‘non- completers’, 97 had no assessment while 75 had 
an assessment and up to one treatment session.
Why did the trial clearly not change the likelihood of CWP 
onset while showing positive effects for a range of secondary 
outcomes (including quality of life)? First, it may be that CBT 
is not effective in relation to preventing CWP onset. We know 
that there is a large body of evidence that CBT (including 
tCBT) is effective in relation to managing CWP, and also for 
managing some of the symptoms which characterised people 
at high risk, but it may not be effective at improving the pain 
in CWP. Our previous trial using CBT in the management of 
CWP while showing large improvement in patient perception 
of their condition and in quality of life, did not demonstrate 
any benefit in terms of the Chronic Pain Grade.10 Second, our 
risk model may not be the causal model. A change in hypothe-
sised risk factors would only effect a change in outcome if the 
relationship was causal. This suggests that it would be beneficial 
to explore, among those at risk, what is the underlying causal 
mechanism. Altered hypothalamic–pituitary–adrenal axis func-
tion is one possible underlying causal mechanism which has been 
investigated.28 Third, it is understood that there are life- course 
influences, specifically early life factors, on the development of 
CWP,29 so it could be that intervening across the adult age range 
is too late to be effecting a change by means of a short- term 
intervention. Fourth, it may be that CWP was a poor choice as 
the primary outcome. There is evidence that people with CWP 
can move in and out of meeting criteria30 and indeed it may be 
that we have identified people who commonly experience CWP 
but recruited them at a time when they did not meet criteria—
and the interpretation would be that the intervention did not 
move participants off that trajectory. Recent data from a longi-
tudinal study in Norway have shown that the transition, among 
people with pain, to CWP did not represent a clinically signifi-
cant change in state.31
It is already known that CBT is effective in the management 
of fibromyalgia11 and this study provides evidence that a wider 
range of patients may benefit in terms of quality of life. In 
total 54.5% of the intervention group considered their health 
had improved (between a little and very much) compared with 
36.9% of the UC group, as well as improvements in fatigue, 
distress and changes in response to symptoms. The incremental 
cost per QALY gained of £1828 (which was robust to different 
assumptions modelled in various sensitivity analyses) means that 
this intervention is highly likely to be cost- effective at the limit, 
which NICE in the UK, is willing to pay. In terms of delivering 
behavioural therapies, it has long been recognised that there is 
a shortage of clinical psychologists in the UK. It is not neces-
sary to have such persons delivering behavioural therapy to all 
such patients even where CBT is identified as appropriate. In this 
study, the intervention was delivered by therapists accredited by 
the British Association for Behaviour and Cognitive Psycho-
therapies. At a minimum this requires a Bachelor of Science 
degree and a 2- year course leading to a postgraduate diploma in 
cognitive–behaviour psychotherapies. Further there has been a 
considerable amount of research in terms of internet- based ther-
apies. The potential advantage of such a self- directed approach 
is that it requires less input by the therapist (usually some-
where between 1 and 15 mins/week). Further, a meta- analysis 
of 20 studies involving 1460 participants showed that internet- 
delivered CBT was effective in the treatment of insomnia,32 
while a meta- analysis of 20 studies involving 1418 participants 
comparing face- to- face and internet- delivered CBT for psychi-
atric and somatic symptoms found that ‘there was no evidence 
to conclude that they were not equivalent’.33 Studies have also 
examined training members of the care team (usually nurses) 
to deliver behavioural therapy in terms of making any service 
for chronic pain sustainable, and these have been shown to be 
effective.34 Thus, we need to consider different professionals 
and ways of delivering CBT, particularly if we widen the group 
Figure 2 Cost- Effectiveness plane and cost- effectiveness acceptability curve between groups (primary analysis using imputed dataset, NHS 
perspective). Cost- effectiveness planes were based on 500 bootstrap cost- effect pairs (adjusted for age, gender, number of risk factors present, 
employment status, centre, baseline EQ- 5D health utility score and baseline cost). EQ- 5D, EuroQol Questionnaire- five dimensions; NHS, National 
Health Service; QALY, quality- adjusted life- year; tCBT, telephone- delivered cognitive–behavioural therapy.
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eligible to receive it, and there is no doubt that the large changes 
to how health services are delivered, caused by COVID-19, will 
only accelerate moves to the greater use of remote delivery of 
care.
In summary, this trial has shown that a short course of 
tCBT does not prevent the onset of CWP in adults assessed 
as being at high risk. It did however positively change most 
other health indicators measured, including quality of life, 
and was highly cost- effective. It demonstrates that a low- cost, 
short- duration intervention benefits a wider range of people 
with musculoskeletal symptoms than previously considered.
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The Scottish Index of multiple deprivation was used to determine the quintile of deprivation of 
participants based on their area of residence, assessed by their postcode (SIMD, 2016).  
 
Details of Secondary Outcomes 
Secondary outcomes collected in the study were as follows: 
 
- Global Impression of Change (of health since entering the trial), a single-item measure of 
seven six categories (very much better, much better, a little better, no change, a little worse, 
much worse and very much worse), although the latter two categories were combined for 
analysis due to low numbers; 
- the presence of pain over the last month and number of pain sites (measured by the 
Widespread Pain Index (score 0-19) of the “research” (or 2010 revised) criteria for 
fibromyalgia (20). In addition, we measured the Symptom Severity Scale (SSS: score 0-12) 
which are also part of the fibromyalgia criteria set. Participants with WPI ≥7 & SSS ≥ 5, or 
WPI 3-6 & SSS ≥9, and who reported having such symptoms for at least 3 months, meet 
criteria for fibromyalgia. 
- the “risk profile” for CWP as assessed by the Illness Behaviour Subscale of the Illness 
Attitudes Scale (16), the Somatic Symptom Scale score (but excluding items on pain) (17), 
and the Sleep Problem Scale (18). The Illness Attitudes Scale measures attitudes and 
concerns about illness and health. A study using principal component analysis (Speckens et 
al, 1996) showed that the IAS consisted of two subscales, one of which related to illness 
behaviour (6 items), scoring from 0-24, with higher scores associated with undertaking 
specific behaviours. The Somatic Symptom Scale was originally devised as a screening tool 
for somatisation and consists of 5 non-pain items (0-5, with higher scores indicating more 
somatic symptoms). The Sleep Problem Scale consists of four items measuring sleep 
problems over the past four weeks with score range 0-20, higher scores indicating greater 
frequency of sleep problems; 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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- psychological distress measured using  the 12-item General Health Questionnaire (GHQ)(20) 
and analysed using an ordinal model with the categories 0 (least distress), 1, 2-5 and 6-12 
(most distress); 
- fatigue measured using the Chalder Fatigue Scale (11 items with scores 0-33, higher scores 
representing more disabling and severe  fatigue) (21);  
- quality of life measured using the five-item, five level EQ-5D-5L (-0.59 representing the worst 
possible quality of life and 1 the best possible) (22);  
- capability using the 5-item ICECAP-A (ICEpop CAPability measure for Adults) which focusses 
on wellbeing, and analysed using an ordinal model with categories 0-0.49 (worst quality of 




Sensitivity analyses were conducted for the primary outcome only. These included an analysis 
excluding participants who did not complete the active intervention (per protocol analysis) and an 
analysis using multiple imputation (see Royston, 2004). For the per protocol analysis, participants in 
the intervention group were included if they had the initial assessment with the therapist and it was 
mutually agreed to stop the treatment, or if they had the initial assessment plus at least 2 more 
sessions with the therapist. Missing values for CWP at each time point were imputed using the mi 
package in STATA using the following variables: age, gender, number of risk factors and GP practice. 
Twenty imputed datasets were created, using an adjusted logistic regression model. An additional 
analysis for CWP incorporating all three follow-up time points in one model was also conducted 
using generalised estimating equations using an unstructured correlation structure (see Zeger et al, 
1988). The model was adjusted for covariates and results expressed as an OR with 95% CI. 
 
Additional requirements in CONSORT reporting of trials  
 
Randomisation: The randomisation was undertaken by a member of the study team contacting, 
using internet or telephone, the trial randomisation centre at the Centre for Healthcare Randomised 
Trials at the University of Aberdeen. The participants were informed of the allocated group during 
the consent/randomisation phone call. The study statistician was blinded to which group received 
the “active” treatment until the statistical analysis had been completed. 
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Generalisability: The trial recruited from very different areas of Scotland. It included urban areas in 
Glasgow and Aberdeen with very different levels of deprivation, rural areas in Aberdeenshire and 
remote areas across the Highlands. Recruitment through a population-sampling frame maximises 
generalisability. Our previous (qualitative) work in terms of telephone delivery of CBT has shown 
that this can improve access both in remote and rural areas (because care can be obtained without 
long distance travel) and in urban areas (since it overcomes, for example, difficulties in getting time 
off work or in arranging suitable care for dependents) (Bee et al, 2010; Bee et al, 2016).   
Harms: It was not envisaged that the intervention would lead to harms, but procedures were 
designed to support any participants who became distressed during the sessions.   
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Table S1: Outcomes by treatment arm at 3 months (Intention to treat analysis) 
Characteristic Randomised groups 
 tCBT (n=500) Usual care (n=496) 
Primary Outcome N (%) N (%) 







Secondary Outcome   
Global impression of change   
Very much better 
Much better 
A little better 
No change 
A little worse 
Much worse 






















CWP risk profile   




Illness Behaviour Score       Mean (SD)[n*] 





8.96 (3.99) [379] 





9.21 (3.86) [441] 
9.16 (5.08) [439] 













 Mean (SD) [n] Mean (SD) [n] 
Chalder Fatigue Score 12.2 (4.2) [372] 13.6 (4.2) [440] 
 Median (IQR) [n] Median (IQR) [n] 
Quality of Life (EQ-5D utility score) 0.74 (0.67 - 0.84) [379] 0.74 (0.65 - 0.84) [442] 
ICECAP-A 0.89 (0.80 - 0.95) [378] 0.89 (0.78 - 0.95) [440] 
Fibromyalgia Research Criteria   
WPI 
SSS 
3 (1 - 4) [370] 
3 (2 – 5) [373] 
3 (1 – 4) [432] 
4 (2 – 5) [433] 
EQ-5D-5L: Euroqol questionnaire – five dimensions – five levels; FRC: fibromyalgia research criteria; GHQ: 
general health questionnaire; ICECAP-A: ICEpop CAPability measure for Adults; IQR: interquartile range; SD: 
standard deviation; SSS: symptom severity scale; tCBT: telephone cognitive behavioural therapy; WPI: 
widespread pain index. * The number of persons for whom a scale score could be calculated  
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Table S2: Outcomes by treatment arm at 24 months (Intention to treat analysis) 
Characteristic Randomised groups 
 tCBT (n=500) Usual care (n=496) 
Primary Outcome N (%) N (%) 







Secondary Outcome   
Global impression of change   
Very much better 
Much better 
A little better 
No change 
A little worse 
Much worse 






















CWP Risk Profile    




Illness behaviour score        Mean (SD)[n*] 




7.75 (4.14) [310] 




8.95 (4.18) [377]  
9.06 (5.0) [376] 













 Mean (SD) [n] Mean (SD) [n] 
Chalder Fatigue Score 13.0 (4.3) [309] 13.9 (4.4) [377] 
 Median (IQR) [n] Median (IQR) [n] 
Quality of Life (EQ-5D utility score) 0.74 (0.68 – 0.84) [313] 0.74 (0.65 – 0.84) [386] 
ICECAP-A 0.91 (0.80 – 0.96) [311] 0.89 (0.79 – 0.95) [386] 
Fibromyalgia Research Criteria Median (IQR) [n] Median (IQR) [n] 
WPI 
SSS 
2 (1 – 4) [306]  
3 (2 – 5) [309] 
2.5 (1 – 4) [370] 
4 (2 – 5) [376] 
EQ-5D-5L: Euroqol questionnaire – five dimensions – five levels; FRC: fibromyalgia research criteria; GHQ: 
general health questionnaire; ICECAP-A: ICEpop CAPability measure for Adults; IQR: interquartile range; SD: 
standard deviation; SSS: symptom severity scale; tCBT: telephone cognitive behavioural therapy; WPI: 
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Table S3: Unit costs applied to value health care resource use (£, 2017/18 UK prices) 
Resource Unit Source Basis of estimate Cost (£) 
NHS health care resource use      
GP  Visit Curtis 2018 9.22 minutes consultation, including qualification and direct staff 37 
Practice nurse Visit Curtis 2015, Curtis 
2018 
Surgery consultation 15.5 minutes 11 
Community physiotherapist Visit Curtis 2018 Assumes 30 minutes consultation  17 
Other community  Visit Curtis 2018 Assumes cost of community physiotherapist 17 
CT – Chiropractor Visit Curtis 2018 Assumes cost of community physiotherapist 17 
CT – Osteopath Visit Curtis 2018 Assumes cost of community physiotherapist 17 
CT – Other Visit Curtis 2018 Assumes cost of community physiotherapist 17 
Outpatient – Rheumatology Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 410 
Rheumatology, WF01B Non-Admitted Face to Face Attendance, 
Follow-up First, 410 Rheumatology (weighted mean cost over 
these two categories) 
150 
Outpatient – Orthopaedics Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 110 
Trauma & Orthopaedics, WF01B, Non-Admitted Face to Face 
Attendance, First, 110 Trauma & Orthopaedics (weighted mean 
cost over these two categories) 
125 
Outpatient – Other Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 191 
Pain Management, WF01B Non-Admitted Face to Face 
Attendance, First, 191 Pain Management (weighted mean cost 
over these two categories) 
149 
Other HCP –  Physiotherapist Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 650 
Physiotherapy, WF01B Non-Admitted Face to Face Attendance, 
First, 650 Physiotherapy (weighted mean cost over these two 
categories) 
55 
Other HCP –  Other Visit NHS Reference Costs Assumes cost of a physiotherapy attendance 55 
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2017/18 
Emergency department  Visit NHS Reference Costs 
2017/18 
180 Accident & Emergency (weighted mean over consultant led 
and non-consultant led) 
136 
Non-elective admission Day NHS Reference Costs 
2017/18 
HD21 Soft Tissue Disorders (mean cost over CC Score 0-2 and CC 
Score 3-5) 
315 
Planned (elective) admission Day NHS Reference Costs 
2017/18 
HD21 Soft Tissue Disorders (mean cost over CC Score 0-2 and CC 
Score 3-5) 
377 
Private (non-NHS) treatment 
resource use 
    
HCP – Doctor Visit UK Beam Trial Mean cost of private specialist visit - uprated 183 
HCP – Physiotherapist Visit BUPA Mean cost of private physiotherapist outpatient attendance  47 
HCP – Chiropractor Visit Wonderling et al 
2004 
Mean cost of a private visit chiropractor or osteopath – uprated  36 
HCP – Osteopath Visit Wonderling et al 
2004 
Mean cost of a private visit chiropractor or osteopath – uprated 36 
HCP – Other (e.g. 
acupuncturist) 
Visit BUPA Assumes mean cost of a private physiotherapist outpatient 
attendance  
47 
HCP – Other  Visit BUPA Assumes mean cost of a private physiotherapist outpatient 
attendance  
47 
Hospital admission Day UK Beam Trial Mean cost of private hospital admission/day – uprated  602 
GP = General practitioner; HCP = Health care professional; CT=Complementary therapist  
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Table S4: Unadjusted mean resource use and costs per patient over 24 months follow-up 
 
Resource use item Usual care, n=496 tCBT, n=500 








Intervention       




NHS primary care       
GP visits 343 8.61 (8.31) 318.44 (307.38) 277 7.51 (8.10) 277.97 (299.86) 
Practice nurse visits 343 4.11 (5.69) 45.19 (62.57) 277 5.23 (11.87) 57.54 (130.61) 
Community physiotherapist visits 343 2.26 (5.43) 38.46 (92.39) 277 1.90 (3.12) 32.22 (64.83) 
Other community health care professional visits 343 0.70 (1.72) 11.90 (29.27) 277 1.20 (3.12) 20.38 (53.99) 
Chiropractor visits 343 0.66 (3.64) 11.30 (61.89) 277 0.59 (4.51) 10.06 (76.65) 
Osteopath visits 343 0.57 (3.06) 9.62 (51.97) 277 0.59 (3.27) 10.00 (55.66) 
Other complementary therapist visits 343 2.14 (7.11) 36.43 (120.98) 277 2.31 (6.97) 39.34 (118.53) 
Total NHS primary care costs 343 - 471.34 (447.94) 277 - 447.51 (434.82) 
NHS hospital care       
Non-elective admission days 343 1.24 (6.01) 474.61 (2,178.77) 277 0.81 (4.86) 311.43 (1,752.32) 
Elective admission days 343 0.98 (2.76) 369.61 (1,042.04) 277 0.78 (2.64) 293.98 (997.85) 
Outpatient rheumatology visits 335 0.21 (0.95) 30.09 (132.36) 272 0.39 (1.46) 54.04 (203.83) 
Outpatient orthopaedics visits 335 0.80 (1.80) 92.42 (206.56) 272 0.67 (1.51) 77.37 (173.08) 
Other outpatient clinic visits 335 2.86 (4.63) 408.51 (662.79) 273 2.27 (3.97) 324.24 (567.88) 
Hospital physiotherapist visits 343 1.14 (2.71) 65.95 (157.40) 277 1.49 (3.69) 86.69 (214.00) 
Other hospital health care professional visits 343 1.26 (2.83) 72.88 (164.27) 277 1.14 (2.46) 66.17 (142.82) 
Total NHS hospital care costs 335 - 1,503.92 (2,731.09) 272 - 1,186.65 (2,425.09) 
Private care        
Admission days 343 0.12 (0.71) 70.02 (426.10) 277 0.14 (0.79) 82.58 (473.55) 
Private doctor visits 343 0.39 (1.96) 72.03 (357.87) 277 0.37 (1.12) 67.39 (205.62) 
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The Scottish Index of multiple deprivation was used to determine the quintile of deprivation of 
participants based on their area of residence, assessed by their postcode (SIMD, 2016).  
 
Details of Secondary Outcomes 
Secondary outcomes collected in the study were as follows: 
 
- Global Impression of Change (of health since entering the trial), a single-item measure of 
seven six categories (very much better, much better, a little better, no change, a little worse, 
much worse and very much worse), although the latter two categories were combined for 
analysis due to low numbers; 
- the presence of pain over the last month and number of pain sites (measured by the 
Widespread Pain Index (score 0-19) of the “research” (or 2010 revised) criteria for 
fibromyalgia (20). In addition, we measured the Symptom Severity Scale (SSS: score 0-12) 
which are also part of the fibromyalgia criteria set. Participants with WPI ≥7 & SSS ≥ 5, or 
WPI 3-6 & SSS ≥9, and who reported having such symptoms for at least 3 months, meet 
criteria for fibromyalgia. 
- the “risk profile” for CWP as assessed by the Illness Behaviour Subscale of the Illness 
Attitudes Scale (16), the Somatic Symptom Scale score (but excluding items on pain) (17), 
and the Sleep Problem Scale (18). The Illness Attitudes Scale measures attitudes and 
concerns about illness and health. A study using principal component analysis (Speckens et 
al, 1996) showed that the IAS consisted of two subscales, one of which related to illness 
behaviour (6 items), scoring from 0-24, with higher scores associated with undertaking 
specific behaviours. The Somatic Symptom Scale was originally devised as a screening tool 
for somatisation and consists of 5 non-pain items (0-5, with higher scores indicating more 
somatic symptoms). The Sleep Problem Scale consists of four items measuring sleep 
problems over the past four weeks with score range 0-20, higher scores indicating greater 
frequency of sleep problems; 
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- psychological distress measured using  the 12-item General Health Questionnaire (GHQ)(20) 
and analysed using an ordinal model with the categories 0 (least distress), 1, 2-5 and 6-12 
(most distress); 
- fatigue measured using the Chalder Fatigue Scale (11 items with scores 0-33, higher scores 
representing more disabling and severe  fatigue) (21);  
- quality of life measured using the five-item, five level EQ-5D-5L (-0.59 representing the worst 
possible quality of life and 1 the best possible) (22);  
- capability using the 5-item ICECAP-A (ICEpop CAPability measure for Adults) which focusses 
on wellbeing, and analysed using an ordinal model with categories 0-0.49 (worst quality of 




Sensitivity analyses were conducted for the primary outcome only. These included an analysis 
excluding participants who did not complete the active intervention (per protocol analysis) and an 
analysis using multiple imputation (see Royston, 2004). For the per protocol analysis, participants in 
the intervention group were included if they had the initial assessment with the therapist and it was 
mutually agreed to stop the treatment, or if they had the initial assessment plus at least 2 more 
sessions with the therapist. Missing values for CWP at each time point were imputed using the mi 
package in STATA using the following variables: age, gender, number of risk factors and GP practice. 
Twenty imputed datasets were created, using an adjusted logistic regression model. An additional 
analysis for CWP incorporating all three follow-up time points in one model was also conducted 
using generalised estimating equations using an unstructured correlation structure (see Zeger et al, 
1988). The model was adjusted for covariates and results expressed as an OR with 95% CI. 
 
Additional requirements in CONSORT reporting of trials  
 
Randomisation: The randomisation was undertaken by a member of the study team contacting, 
using internet or telephone, the trial randomisation centre at the Centre for Healthcare Randomised 
Trials at the University of Aberdeen. The participants were informed of the allocated group during 
the consent/randomisation phone call. The study statistician was blinded to which group received 
the “active” treatment until the statistical analysis had been completed. 
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Generalisability: The trial recruited from very different areas of Scotland. It included urban areas in 
Glasgow and Aberdeen with very different levels of deprivation, rural areas in Aberdeenshire and 
remote areas across the Highlands. Recruitment through a population-sampling frame maximises 
generalisability. Our previous (qualitative) work in terms of telephone delivery of CBT has shown 
that this can improve access both in remote and rural areas (because care can be obtained without 
long distance travel) and in urban areas (since it overcomes, for example, difficulties in getting time 
off work or in arranging suitable care for dependents) (Bee et al, 2010; Bee et al, 2016).   
Harms: It was not envisaged that the intervention would lead to harms, but procedures were 
designed to support any participants who became distressed during the sessions.   
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Table S1: Outcomes by treatment arm at 3 months (Intention to treat analysis) 
Characteristic Randomised groups 
 tCBT (n=500) Usual care (n=496) 
Primary Outcome N (%) N (%) 







Secondary Outcome   
Global impression of change   
Very much better 
Much better 
A little better 
No change 
A little worse 
Much worse 






















CWP risk profile   




Illness Behaviour Score       Mean (SD)[n*] 





8.96 (3.99) [379] 





9.21 (3.86) [441] 
9.16 (5.08) [439] 













 Mean (SD) [n] Mean (SD) [n] 
Chalder Fatigue Score 12.2 (4.2) [372] 13.6 (4.2) [440] 
 Median (IQR) [n] Median (IQR) [n] 
Quality of Life (EQ-5D utility score) 0.74 (0.67 - 0.84) [379] 0.74 (0.65 - 0.84) [442] 
ICECAP-A 0.89 (0.80 - 0.95) [378] 0.89 (0.78 - 0.95) [440] 
Fibromyalgia Research Criteria   
WPI 
SSS 
3 (1 - 4) [370] 
3 (2 – 5) [373] 
3 (1 – 4) [432] 
4 (2 – 5) [433] 
EQ-5D-5L: Euroqol questionnaire – five dimensions – five levels; FRC: fibromyalgia research criteria; GHQ: 
general health questionnaire; ICECAP-A: ICEpop CAPability measure for Adults; IQR: interquartile range; SD: 
standard deviation; SSS: symptom severity scale; tCBT: telephone cognitive behavioural therapy; WPI: 
widespread pain index. * The number of persons for whom a scale score could be calculated  
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Table S2: Outcomes by treatment arm at 24 months (Intention to treat analysis) 
Characteristic Randomised groups 
 tCBT (n=500) Usual care (n=496) 
Primary Outcome N (%) N (%) 







Secondary Outcome   
Global impression of change   
Very much better 
Much better 
A little better 
No change 
A little worse 
Much worse 






















CWP Risk Profile    




Illness behaviour score        Mean (SD)[n*] 




7.75 (4.14) [310] 




8.95 (4.18) [377]  
9.06 (5.0) [376] 













 Mean (SD) [n] Mean (SD) [n] 
Chalder Fatigue Score 13.0 (4.3) [309] 13.9 (4.4) [377] 
 Median (IQR) [n] Median (IQR) [n] 
Quality of Life (EQ-5D utility score) 0.74 (0.68 – 0.84) [313] 0.74 (0.65 – 0.84) [386] 
ICECAP-A 0.91 (0.80 – 0.96) [311] 0.89 (0.79 – 0.95) [386] 
Fibromyalgia Research Criteria Median (IQR) [n] Median (IQR) [n] 
WPI 
SSS 
2 (1 – 4) [306]  
3 (2 – 5) [309] 
2.5 (1 – 4) [370] 
4 (2 – 5) [376] 
EQ-5D-5L: Euroqol questionnaire – five dimensions – five levels; FRC: fibromyalgia research criteria; GHQ: 
general health questionnaire; ICECAP-A: ICEpop CAPability measure for Adults; IQR: interquartile range; SD: 
standard deviation; SSS: symptom severity scale; tCBT: telephone cognitive behavioural therapy; WPI: 
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Table S3: Unit costs applied to value health care resource use (£, 2017/18 UK prices) 
Resource Unit Source Basis of estimate Cost (£) 
NHS health care resource use      
GP  Visit Curtis 2018 9.22 minutes consultation, including qualification and direct staff 37 
Practice nurse Visit Curtis 2015, Curtis 
2018 
Surgery consultation 15.5 minutes 11 
Community physiotherapist Visit Curtis 2018 Assumes 30 minutes consultation  17 
Other community  Visit Curtis 2018 Assumes cost of community physiotherapist 17 
CT – Chiropractor Visit Curtis 2018 Assumes cost of community physiotherapist 17 
CT – Osteopath Visit Curtis 2018 Assumes cost of community physiotherapist 17 
CT – Other Visit Curtis 2018 Assumes cost of community physiotherapist 17 
Outpatient – Rheumatology Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 410 
Rheumatology, WF01B Non-Admitted Face to Face Attendance, 
Follow-up First, 410 Rheumatology (weighted mean cost over 
these two categories) 
150 
Outpatient – Orthopaedics Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 110 
Trauma & Orthopaedics, WF01B, Non-Admitted Face to Face 
Attendance, First, 110 Trauma & Orthopaedics (weighted mean 
cost over these two categories) 
125 
Outpatient – Other Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 191 
Pain Management, WF01B Non-Admitted Face to Face 
Attendance, First, 191 Pain Management (weighted mean cost 
over these two categories) 
149 
Other HCP –  Physiotherapist Visit NHS Reference Costs 
2017/18 
WF01A Non-Admitted Face to Face Attendance, Follow-up, 650 
Physiotherapy, WF01B Non-Admitted Face to Face Attendance, 
First, 650 Physiotherapy (weighted mean cost over these two 
categories) 
55 
Other HCP –  Other Visit NHS Reference Costs Assumes cost of a physiotherapy attendance 55 
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2017/18 
Emergency department  Visit NHS Reference Costs 
2017/18 
180 Accident & Emergency (weighted mean over consultant led 
and non-consultant led) 
136 
Non-elective admission Day NHS Reference Costs 
2017/18 
HD21 Soft Tissue Disorders (mean cost over CC Score 0-2 and CC 
Score 3-5) 
315 
Planned (elective) admission Day NHS Reference Costs 
2017/18 
HD21 Soft Tissue Disorders (mean cost over CC Score 0-2 and CC 
Score 3-5) 
377 
Private (non-NHS) treatment 
resource use 
    
HCP – Doctor Visit UK Beam Trial Mean cost of private specialist visit - uprated 183 
HCP – Physiotherapist Visit BUPA Mean cost of private physiotherapist outpatient attendance  47 
HCP – Chiropractor Visit Wonderling et al 
2004 
Mean cost of a private visit chiropractor or osteopath – uprated  36 
HCP – Osteopath Visit Wonderling et al 
2004 
Mean cost of a private visit chiropractor or osteopath – uprated 36 
HCP – Other (e.g. 
acupuncturist) 
Visit BUPA Assumes mean cost of a private physiotherapist outpatient 
attendance  
47 
HCP – Other  Visit BUPA Assumes mean cost of a private physiotherapist outpatient 
attendance  
47 
Hospital admission Day UK Beam Trial Mean cost of private hospital admission/day – uprated  602 
GP = General practitioner; HCP = Health care professional; CT=Complementary therapist  
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Table S4: Unadjusted mean resource use and costs per patient over 24 months follow-up 
 
Resource use item Usual care, n=496 tCBT, n=500 








Intervention       




NHS primary care       
GP visits 343 8.61 (8.31) 318.44 (307.38) 277 7.51 (8.10) 277.97 (299.86) 
Practice nurse visits 343 4.11 (5.69) 45.19 (62.57) 277 5.23 (11.87) 57.54 (130.61) 
Community physiotherapist visits 343 2.26 (5.43) 38.46 (92.39) 277 1.90 (3.12) 32.22 (64.83) 
Other community health care professional visits 343 0.70 (1.72) 11.90 (29.27) 277 1.20 (3.12) 20.38 (53.99) 
Chiropractor visits 343 0.66 (3.64) 11.30 (61.89) 277 0.59 (4.51) 10.06 (76.65) 
Osteopath visits 343 0.57 (3.06) 9.62 (51.97) 277 0.59 (3.27) 10.00 (55.66) 
Other complementary therapist visits 343 2.14 (7.11) 36.43 (120.98) 277 2.31 (6.97) 39.34 (118.53) 
Total NHS primary care costs 343 - 471.34 (447.94) 277 - 447.51 (434.82) 
NHS hospital care       
Non-elective admission days 343 1.24 (6.01) 474.61 (2,178.77) 277 0.81 (4.86) 311.43 (1,752.32) 
Elective admission days 343 0.98 (2.76) 369.61 (1,042.04) 277 0.78 (2.64) 293.98 (997.85) 
Outpatient rheumatology visits 335 0.21 (0.95) 30.09 (132.36) 272 0.39 (1.46) 54.04 (203.83) 
Outpatient orthopaedics visits 335 0.80 (1.80) 92.42 (206.56) 272 0.67 (1.51) 77.37 (173.08) 
Other outpatient clinic visits 335 2.86 (4.63) 408.51 (662.79) 273 2.27 (3.97) 324.24 (567.88) 
Hospital physiotherapist visits 343 1.14 (2.71) 65.95 (157.40) 277 1.49 (3.69) 86.69 (214.00) 
Other hospital health care professional visits 343 1.26 (2.83) 72.88 (164.27) 277 1.14 (2.46) 66.17 (142.82) 
Total NHS hospital care costs 335 - 1,503.92 (2,731.09) 272 - 1,186.65 (2,425.09) 
Private care        
Admission days 343 0.12 (0.71) 70.02 (426.10) 277 0.14 (0.79) 82.58 (473.55) 
Private doctor visits 343 0.39 (1.96) 72.03 (357.87) 277 0.37 (1.12) 67.39 (205.62) 
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